author-photo

Rachel Kloss Silverman

Merck & Co.

4

Papers

107

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (31)
First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (41)
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (23)